Aqupla (nedaplatin) / Simcere - LARVOL DELTA

A Single-Center, Single-Arm Exploratory Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma (ChiCTR) - P4 | N=20 | Not yet recruiting | Sponsor: Shandong Second People's Hospital; Shandong Second People's Hospital

New P4 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Long-term significant efficacy of gemcitabine combined with nedaplatin in persistent refractory nasopharyngeal carcinoma involving the cavernous sinus and distant metastasis:a case report (ChiCTR) - P=N/A | N=1 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University

New trial • Head and Neck Cancer • Lung Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Comparison of nedaplatin and cisplatin in concurrent chemoradiotherapy for cervical cancer: a systematic review and meta-analysis. (PubMed, Int J Clin Oncol) - "Nedaplatin showed fewer adverse effects and comparable or improved short-term outcomes compared with cisplatin. These findings support nedaplatin as a potential alternative for patients who are cisplatin-intolerant or frail. Confirmation in large, high-quality trials with long-term follow-up and patient-reported outcomes is warranted."

Journal • Retrospective data • Cervical Cancer • Hematological Disorders • Hepatology • Liver Failure • Oncology • Solid Tumor

Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - P2 | N=62 | Active, not recruiting | Sponsor: Sun Yat-sen University

New P2 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

A novel effect of bevacizumab in reducing characteristic pigmentation in Peutz-Jeghers syndrome: a case report and literature review. (PubMed, Front Oncol) - "Initial concurrent chemoradiation (paclitaxel with either nedaplatin or cisplatin with volumetric modulated arc therapy) achieved partial response, while subsequent maintenance therapy combining bevacizumab with chemotherapy induced complete radiographic remission. These findings challenge the conventional paradigm of PJS pigmentation as a static feature by demonstrating that VEGF-mediated angiogenesis concurrently drives carcinogenesis and melanin deposition. The case highlights three key implications, namely: (1) validation of bevacizumab's dual therapeutic potential against PJS-associated malignancies and cutaneous manifestations, (2) proposal of mucocutaneous pigmentation as a dynamic biomarker for treatment response monitoring, and (3) urgent need for prospective clinical trials evaluating VEGF inhibition in PJS through longitudinal surveillance of oncologic control and pigment dynamics."

Journal • Cervical Adenocarcinoma • Cervical Cancer • Oncology

A prognostic nomogram integrating Epstein-Barr virus DNA and specific inflammatory indices for early recurrent or metastatic nasopharyngeal carcinoma after first-line nedaplatin-based therapy. (PubMed, Discov Oncol) - "This study successfully constructed a nomogram model for patients with NPC who experienced recurrence or metastasis within ten years following the completion of first-line treatment with nedaplatin. This model functions as an adjunct to the 8th edition UICC/AJCC staging system and provides significant support for clinical decision-making processes."

Journal • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Robot-Assisted Mediastinoscopic Esophagectomy Following Immunotherapy-Induced Interstitial Pneumonia in a High-Risk Patient with Esophageal Cancer (PubMed, Gan To Kagaku Ryoho) - "A 70-year-old man had achieved the long-term complete response to pembrolizumab maintenance after carboplatin and pemetrexed chemotherapy...After diagnosis of esophageal cancer(cT3rN0M0, cStage Ⅱ), neoadjuvant docetaxel, nedaplatin, and 5-fluorouracil(UDON)chemotherapy resulted in tumor shrinkage, but interstitial pneumonia worsened, necessitating the reintroduction of corticosteroids...Robotic assistance enabled precise dissection, and NIM use facilitated nerve preservation leading to aspiration pneumonia. This case demonstrates that combining minimally invasive robot-assisted mediastinal esophagectomy with NIM system, UDON chemotherapy, and nutritional support enable favorable outcomes in high-risk esophageal cancer patients with ICI-related irAEs."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Infectious Disease • Interstitial Lung Disease • Lung Cancer • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma

Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial. (PubMed, EClinicalMedicine) - P2 | "Patients received neoadjuvant therapy comprised of albumin-bound paclitaxel, nedaplatin and toripalimab every 3 weeks, for 2 cycles, followed by CCRT (total dose 60Gy in cohort A, 50Gy in cohort B, combined with oral capecitabine). Further investigation is warranted. None."

Journal • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Pneumonia • Squamous Cell Carcinoma

Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial. (PubMed, JAMA Oncol) - P2 | "Patients were randomly assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2, and platinum [cisplatin, 75 mg/m2; carboplatin, area under the curve, 5; or nedaplatin, 100 mg/m2]) or chemotherapy alone, followed by surgery after 4 to 6 weeks. This randomized clinical trial found that among patients with resectable stage IIIA or IIIB (T3N2) NSCLC, camrelizumab plus chemotherapy, compared with chemotherapy alone, significantly improved the pCR rate with manageable toxic effects. ClinicalTrials.gov Identifier: NCT04338620."

Clinical • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Case of Laparoscopic Lateral Segmentectomy for Metachronous Liver Metastasis from Cervical Cancer (PubMed, Gan To Kagaku Ryoho) - "She underwent chemoradiotherapy, which included whole pelvic irradiation(50 Gy), intracavitary irradiation(24 Gy), and 6 cycles of nedaplatin therapy at the gynecology department...While liver metastasis in cervical cancer is not uncommon, isolated, metachronous liver metastasis is rare. Including our case, there have been only 8 such reports in Japan, making this a rare case."

Journal • Cervical Cancer • Gynecology • Oncology • Solid Tumor • Squamous Cell Carcinoma • Uterine Cancer

Prognostic Impact of Carboplatin-Paclitaxel versus Nedaplatin-Paclitaxel in Advanced Epithelial Ovarian Cancer- A real world Study from Single Cancer Center (SGO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

Adebrelimab combined with albumin-paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma: A multicenter, single-arm, phase II clinical study. (ASCO-GI 2026) - P2 | "The neoadjuvant therapy with adebrelimab, albumin-paclitaxel and nedaplatin showed encouraging antitumor activity and was well-tolerated in patients with locally advanced resectable ESCC, achieving pCR in a subset of patients. These supportive results warrant further investigation in ongoing phase II studies."

Clinical • Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Cancer • Oncology

Induction chemotherapy with nedaplatin, docetaxel and 5-fluorouracil followed by concurrent nedaplatin and radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A single arm, open label, phase II clinical trial. (PubMed, Transl Oncol) - P2 | "Induction chemotherapy with nedaplatin, docetaxel, and 5-fluorouracil, followed by concurrent nedaplatin with intensity-modulated radiotherapy, demonstrated promising antitumor activity and manageable toxicities in locoregionally advanced nasopharyngeal carcinoma patients."

Journal • P2 data • Fatigue • Hematological Disorders • Leukopenia • Mucositis • Nasopharyngeal Carcinoma • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia

Induction chemoimmunotherapy followed by concurrent radiotherapy in patients with locally advanced esophageal cancer: a single-arm phase 2 trial. (PubMed, Oncologist) - "This regimen of induction chemoimmunotherapy followed by concurrent chemoradiotherapy and maintenance immunotherapy demonstrated promising survival outcomes, a manageable safety profile, and a preserved QoL, thereby offering a viable nonsurgical alternative for patients with locally advanced ESCC."

Journal • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Hematological Disorders • Oncology • Squamous Cell Carcinoma

Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study. (PubMed, BMC Med) - P2 | "The chemoimmunotherapy regimen shows promising efficacy as a conversion therapy in improving surgical resectability and survival outcomes with manageable TRAEs, and does not delay surgery."

Journal • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

A 66-Year-Old Woman with EGFR-Mutant Lung Adenocarcinoma and Brain Metastases Achieving 96-Month Overall Survival with serially deploying three distinct third-generation EGFR-TKIs (ESMO Asia 2025) - "First-line icotinib plus paclitaxel/nedaplatin was given and achieved PR and 36-month PFS...Osimertinib 80mg qd combined with pemetrexed chemotherapy for 5 cycles, followed by osimertinib monotherapy, yielded 25-month PFS until isolated CNS progression. Despite concomitant whole-brain radiotherapy and bevacizumab with Osimertinib, intracranial lesions advanced...This exceptional survival in advanced EGFR+ NSCLC was achieved through initial chemo-TKI therapy, sequential third-generation TKIs (osi→almo→furmo) for CNS control, and furmonertinib dose escalation for late CNS progression. The persistent TP53 co-mutation suggests a resistance mechanism, while PD-L1 negativity excluded immunotherapy, demonstrating the efficacy of optimized TKI sequencing alone."

Clinical • IO biomarker • Brain Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1 • TP53

Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Zhejiang Cancer Hospital

New P2 trial • Breast Cancer • Oncology • Solid Tumor

Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical trial (ESMO Asia 2025) - P2 | "After ER, all patients received concurrent CRT: 45 Gy in 25 fractions (1.8 Gy/fraction), boosted to 54 Gy for positive margins, plus weekly nedaplatin (25 mg/m2) and paclitaxel liposome (45 mg/m2). ER plus adjuvant CRT shows safety and efficacy in stage I ESCC with pathological high-risk features. Phase III randomized trials are required to confirm its benefits."

Clinical • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Advanced ovarian cancer with malignant bowel obstruction treated with multidisciplinary therapy resulting in long progression-free survival: a case report. (PubMed, BMC Womens Health) - "Patients with advanced ovarian cancer who are initially diagnosed with an inoperable malignant bowel obstruction may still derive a substantial survival benefit from an integrated multidisciplinary treatment regimen. The findings of this study challenge the current negative prognosis of such patients and highlight the need for prospective studies to further explore the potential benefits of this approach."

Journal • Breast Cancer • Gynecologic Cancers • Hematological Malignancies • Immunology • Infectious Disease • Oncology • Ovarian Cancer • Solid Tumor

Kirsten rat sarcoma G12C inhibitor treatment for a patient with relapsed metastatic lung adenocarcinoma: A case report. (PubMed, World J Clin Cases) - "After multiple-line treatment including chemotherapy, targeted therapy, and immunotherapy, disease control was achieved in a case of advanced pulmonary adenocarcinoma carrying the KRAS G12C mutation by mutation-specific inhibitor therapy, and the adverse reactions to the therapy were tolerable."

IO biomarker • Journal • Preclinical • Cough • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Sarcoma • Solid Tumor • KRAS

Efficacy of Platinum-based Chemotherapy for Platinum-sensitive Recurrent Ovarian Cancer During PARP Inhibitor Treatment: A Multicenter Retrospective Study. (PubMed, Anticancer Res) - "Subsequent platinum-based chemotherapy in patients with platinum-sensitive recurrence during PARP inhibitor treatment demonstrated a low response rate and short PFS."

Journal • Platinum sensitive • Retrospective data • Cardiovascular • Constipation • Fallopian Tube Cancer • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Leukopenia • Neutropenia • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • Thrombocytopenia

Otoprotective measures for cisplatin-based chemoradiotherapy-induced toxicity in patients with head and neck cancer: a systematic review and meta-analysis. (PubMed, Support Care Cancer) - "Through our systematic review, we identified a limited number of studies of measures to prevent the ototoxic effects of high-dose cisplatin-based CRT. Most studies had negative results, small patient populations, and were of low quality. Only low-dose cisplatin-based CRT tended to reduce the incidence of ototoxicity while maintaining survival data similar to those of high-dose cisplatin-based CRT."

Journal • Retrospective data • Review • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Exploratory clinical study of Iparomlimab and Tuvonralimab (QL1706) in combination with albumin paclitaxel and nedaplatin for locally advanced resectable squamous cell carcinoma of the esophagus (ESCC) (ChiCTR) - P=N/A | N=30 | Not yet recruiting | Sponsor: Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital

New trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Chromosome 11q13 amplification as a decision-making biomarker for anti-PD-1 immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma: a prospective cohort study. (PubMed, Front Immunol) - P=N/A | "Based on 11q13 amplification status, non-amplified patients received PD-1 inhibitor monotherapy or combination therapy with chemotherapy, while amplified patients were treated with cetuximab and chemotherapy. Nedaplatin was used in place of cisplatin if necessary...Patients without 11q13 amplification exhibited better responses to anti-PD-1 therapy, providing insights into optimizing treatment strategies. Chinese Clinical Trial Registry identifier, ChiCTR2000035635."

Biomarker • IO biomarker • Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial. (PubMed, Int J Cancer) - "The concurrent chemotherapy regimen comprised weekly doses of paclitaxel and nedaplatin for 5 weeks. SIB-RT should be realized as the essential treatment modality for inoperable ESCC. SIB-RT + CT should be the preferred treatment option, as it affords a superior treatment response and greater dysphagia relief."

Journal • P3 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastrointestinal Disorder • Hematological Disorders • Leukopenia • Oncology • Squamous Cell Carcinoma